Clinical Trials
3
Active:1
Completed:1
Trial Phases
2 Phases
Phase 2:2
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Not Applicable
1 (33.3%)Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema
Phase 2
Active, not recruiting
- Conditions
- Diabetic Macular Edema
- Interventions
- Device: Semi-automated suprachoroidal illuminated microcatheter
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Oxular Limited
- Target Recruit Count
- 3
- Registration Number
- NCT05697809
- Locations
- 🇺🇸
Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸Blue Ocean Clinical Research West, Clearwater, Florida, United States
🇺🇸University Retina and Macula Associates, Oak Forest, Illinois, United States
Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
Phase 2
Completed
- Conditions
- Diabetic Macular Edema
- Interventions
- Device: Semi-automated Suprachoroidal Microcatheter
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Oxular Limited
- Target Recruit Count
- 25
- Registration Number
- NCT05512962
- Locations
- 🇺🇸
California Retina Consultants, Bakersfield, California, United States
🇺🇸Retina Consultants of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Austin Retina Associates, Austin, Texas, United States
Oxulumis®, Suprachoroidal Drug Administration of Triesence® in Diabetic Macular Edema
Not Applicable
Withdrawn
- Conditions
- Diabetic Macular Edema
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Oxular Limited
- Registration Number
- NCT05172401
News
No news found